|
gptkbp:instance_of
|
gptkb:pharmaceuticals
|
|
gptkbp:academic_programs
|
gptkb:Dr._Caroline_L._Dorsey
|
|
gptkbp:acquisition
|
gptkb:Schering-Plough_Corporation
gptkb:Acceleron_Pharma
gptkb:Schering-Plough
|
|
gptkbp:advertising
|
gptkb:Dr._Christine_Carr
gptkb:Dr._Julie_Gerberding
gptkb:Dr._Caroline_L._Dorsey
|
|
gptkbp:ceo
|
gptkb:Robert_M._Davis
|
|
gptkbp:conducts_research_on
|
gptkb:Dr._Roger_Perlmutter
|
|
gptkbp:cultural_diversity
|
gptkb:Dr._Michael_J._Mc_Guire
|
|
gptkbp:employees
|
approximately 74,000
|
|
gptkbp:founded
|
1891
|
|
gptkbp:founder
|
gptkb:George_W._Merck
|
|
gptkbp:governance
|
gptkb:Dr._Roger_Perlmutter
|
|
gptkbp:has_authority_over
|
gptkb:Dr._Kenneth_C._Frazier
|
|
gptkbp:head_of_clinical_operations
|
gptkb:Dr._John_C._Lechleiter
|
|
gptkbp:head_of_global_health
|
gptkb:Dr._Julie_Gerberding
|
|
gptkbp:head_of_health_economics
|
gptkb:Dr._Susan_M._Hockfield
|
|
gptkbp:head_of_manufacturing_operations
|
gptkb:Dr._Michael_J._Mc_Guire
|
|
gptkbp:head_of_market_access
|
gptkb:Dr._John_C._Lechleiter
|
|
gptkbp:head_of_medical_affairs
|
gptkb:Dr._Richard_A._Gonzalez
|
|
gptkbp:head_of_pharmacovigilance
|
gptkb:Dr._David_A._Hager
|
|
gptkbp:head_of_pricing_strategy
|
gptkb:Dr._Thomas_C._O'_Brien
|
|
gptkbp:head_of_state
|
gptkb:Dr._David_W._Johnson
gptkb:Dr._Roger_Perlmutter
gptkb:Dr._Susan_M._Hockfield
gptkb:Dr._David_A._Hager
gptkb:Dr._Michael_J._Mc_Guire
gptkb:Dr._Thomas_C._O'_Brien
|
|
gptkbp:headquarters
|
gptkb:Kenilworth,_New_Jersey
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Merck & Co., Inc.
|
|
gptkbp:industry
|
gptkb:pharmaceuticals
|
|
gptkbp:investment
|
gptkb:Dr._David_A._Hager
|
|
gptkbp:legal_issue
|
gptkb:In_re:_Merck_&_Co.,_Inc._Securities_Litigation
|
|
gptkbp:partnership
|
gptkb:Astra_Zeneca
gptkb:Bristol-Myers_Squibb
gptkb:IAVI
|
|
gptkbp:philanthropy
|
gptkb:Merck_Foundation
|
|
gptkbp:products
|
antibiotics
vaccines
oncology drugs
|
|
gptkbp:provides_training_for
|
gptkb:Dr._John_C._Lechleiter
gptkb:Dr._Kenneth_C._Frazier
|
|
gptkbp:public_relations
|
gptkb:Dr._Richard_A._Gonzalez
gptkb:Dr._Christine_Carr
|
|
gptkbp:regulatory_compliance
|
gptkb:Dr._Susan_M._Hockfield
gptkb:Dr._Julie_Gerberding
|
|
gptkbp:related_products
|
gptkb:Lynparza
gptkb:Cimzia
gptkb:Cervarix
gptkb:Procrit
gptkb:Vioxx
gptkb:Tremfya
gptkb:Januvia
gptkb:Bavencio
gptkb:Zostavax
gptkb:Rebif
gptkb:Zetia
gptkb:Gardasil
gptkb:Belsomra
gptkb:Isentress
gptkb:Keytruda
gptkb:Lenvima
gptkb:Prevnar_13
gptkb:Singulair
gptkb:Vaxchora
gptkb:Vaxelis
gptkb:Vaxneuvance
gptkb:Zepatier
Emend
Keytruda (pembrolizumab)
|
|
gptkbp:research
|
gptkb:cancer_treatment
vaccine development
HIV treatment
diabetes treatment
cancer immunotherapy
|
|
gptkbp:revenue
|
$48.7 billion (2020)
$59.3 billion (2022)
|
|
gptkbp:social_responsibility
|
gptkb:Dr._David_W._Johnson
|
|
gptkbp:stock_symbol
|
MRK
|
|
gptkbp:strategic_goals
|
gptkb:Dr._Richard_A._Gonzalez
|
|
gptkbp:strategy
|
gptkb:Dr._John_C._Lechleiter
|
|
gptkbp:subsidiaries
|
gptkb:Merck_Sharp_&_Dohme_Corp.
|
|
gptkbp:subsidiary
|
gptkb:Merck_Sharp_&_Dohme
|
|
gptkbp:supply_chain
|
gptkb:Dr._John_C._Lechleiter
gptkb:Dr._Kenneth_C._Frazier
|
|
gptkbp:sustainability
|
gptkb:Dr._Caroline_L._Dorsey
|
|
gptkbp:user_engagement
|
gptkb:Dr._Christine_Carr
|
|
gptkbp:website
|
www.merck.com
|
|
gptkbp:bfsParent
|
gptkb:Merck_Healthcare
|
|
gptkbp:bfsLayer
|
5
|